SANTA ANA, Calif., April 12, 2011 /PRNewswire/ -- AquaStar Holdings, Inc. (Pink Sheets: RPPR) is pleased to announce that the Company's wholly-owned subsidiary, SUTIMCo, has signed a Venture Acceleration Agreement with Capwave Sensor, Inc., valued at $2,790,000. Capwave is the maker of a revolutionary portable Enzyme-Linked ImmunoSorbent Assay (ELISA) test platform. According to the terms of the Agreement, SUTIMCo will assist Capwave with development and commercialization of its technology for a period of three years at $77,500 per month.
Developed at the State University of New York Binghamton by Professor Omowunmi Sadik, Capwave is a rapid, sensitive, and portable Enzyme-Linked ImmunoSorbent Assay (ELISA) platform for use anywhere antibody based testing can be done and is capable of detecting Bioweapons (anthrax, bacillus globigii), Biomarkers (cancer, stem cells), Toxins (E. coli and salmonella in foodborne illness), Contaminants and Diseases (both viral and bacterial). According to the Centers for Disease Control and Prevention (CDC), about 48 million people (1 in 6 Americans) get sick, 128,000 are hospitalized, and 3,000 die each year from foodborne diseases. The ability to detect the foodborne pathogens responsible for these illnesses in a timely fashion has the potential to offer faster treatment, reduce hospital stays and prevent deaths.
SUTIMCo operates as a Venture Accelerator, offering development services to start-up companies for up to three years. The company launches and manages businesses in health & wellness, energy/environmental, advanced materials, sensors and electronic technology ventures to build upon the research of a host of prestigious Universities across the United States. SUTIMCo's business model and methodologies help create high growth companies taking innovation from laboratory to marketplace.
"We are excited to have the o
|SOURCE AquaStar Holdings, Inc.|
Copyright©2010 PR Newswire.
All rights reserved